(Q39785314)

14 September 2017

title

Development of a bayesian forecasting method for warfarin dose individualization (English)

1 reference

14 September 2017

1 reference

2

Stephen B Duffull

1 reference

14 September 2017

Daniel F B Wright

1

1 reference

14 September 2017

publication date

8 February 2011

1 reference

14 September 2017

published in

Pharmaceutical Research

1 reference

14 September 2017

volume

28

1 reference

14 September 2017

issue

5

1 reference

14 September 2017

page(s)

1100-1111

1 reference

Estimation of the warfarin dose with clinical and pharmacogenetic data

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Frequency of adverse events in patients with poor anticoagulation: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Delayed discharges due to initiation of warfarin in atrial fibrillation: a prospective audit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Effect of study setting on anticoagulation control: a systematic review and metaregression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Warfarin dose management affects INR control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Pharmacogenetics of warfarin: current status and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Integration of genetic, clinical, and INR data to refine warfarin dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Forecasting individual pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

The use of simulated annealing for finding optimal population designs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Target concentration intervention: beyond Y2K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

A computer program for long term anticoagulation control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

A Bayesian method based on clotting factor activity for the prediction of maintenance warfarin dosage regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Computer control of anticoagulant dose for therapeutic management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Assessment of an age-adjusted warfarin initiation protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Poor agreement among prothrombin time international normalized ratio methods: comparison of seven commercial reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11095-011-0369-X

21 January 2018

12 December 2020

Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation

1 reference

12 December 2020

Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model

1 reference

12 December 2020

Systems and microcomputer approach to anticoagulant therapy

1 reference

12 December 2020

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group

1 reference

12 December 2020

Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

1 reference

12 December 2020

Investigation of the Effects of Herbal Medicines on Warfarin Response in Healthy Subjects: A Population Pharmacokinetic-Pharmacodynamic Modeling Approach

1 reference

12 December 2020

A pharmacokinetic simulation model for ivabradine in healthy volunteers

1 reference

12 December 2020

Evaluation of a computer-assisted method for individualized anticoagulation: retrospective and prospective studies with a pharmacodynamic model

1 reference

12 December 2020

Pharmacodynamics of warfarin at steady state

1 reference

12 December 2020

Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated PRogram for Oral Anticoagulant Treatment).

1 reference

12 December 2020

Pharmacokinetics of warfarin enantiomers: A search for intrasubject correlations

1 reference

12 December 2020

Computer-aided long-term anticoagulation therapy

1 reference

12 December 2020

Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose

1 reference

12 December 2020

10.1007/S11095-011-0369-X

Identifiers

DOI

1 reference

14 September 2017

1 reference